We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Servier Renews and Expands License to Aureus

Servier Renews and Expands License to Aureus

Servier Renews and Expands License to Aureus

Servier Renews and Expands License to Aureus

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Servier Renews and Expands License to Aureus "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Aureus Pharma has announced that Servier has both renewed their previous license to Aureus’ AurSCOPE ADME/Drug-Drug Interactions (ADME/DDI) knowledge database and expanded the license to include AurSCOPE GPCR as well.

Servier became Aureus’ first customer of the AurSCOPE ADME/DDI knowledgebase in 2002.  During the subsequent years, Aureus and Servier have collaborated closely to develop and enhance the AurSCOPE ADME/DDI. 

This knowledge database contains all relevant biological and chemical information related to the metabolic properties of drugs and is designed to assist in the identification of potential drug-drug interactions. 

"We have found that Aureus Pharma’s high quality ADME/ Drug-Drug Interaction knowledge databases are a source of crucial information in identifying potential adverse drug-drug interactions," said Dr. Bernard Marchand, Servier’s Director of Biopharmacy.

"We also look forward to applying the AurSCOPE GPCR knowledgebase in a variety of our disease targeted programs," added Dr. Emmanuel Canet, Vice President Research at Servier.

"We are delighted that Servier has chosen to continue their collaboration with Aureus Pharma," said Dr. Andre Michel, CEO of Aureus Pharma. 

"Strong partnership with pharmaceutical companies such as Servier is strategic to Aureus in the ongoing development of solutions fitting with the needs of our end users."